Tempus, Caris, and Natera see enormous opportunity in genomics—but reimbursement determines the pace. Our new AI-generated white paper compares November earnings calls with prior-quarter expectations, examining MolDX coverage, payer pricing, clinical evidence, and promises still awaiting payment.
Here's a summary:
- Tempus AI, Caris, and Natera report strong demand for genomic testing, but reimbursement determines how quickly new products become sustainable businesses. Comparing November earnings calls with the prior quarter reveals distinct strategies.
- Tempus anticipates substantial oncology pricing gains while pacing MRD expansion around coverage.
- Caris expects higher liquid-biopsy reimbursement to help finance new monitoring and detection products.
- Natera is converting clinical evidence into broader coverage, including a new MolDX indication for liver cancer surveillance. Several earlier expectations remain unresolved, particularly payment for emerging applications and Japanese commercialization.
- Across the companies, the key distinction is between technical performance, clinical utility, coverage, and actual collections. Competitive advantage increasingly depends on generating persuasive evidence and financing the long interval before reliable payment.
Find the 15-page report in the cloud HERE.
